Algeria Key takeaways
- In the 2026 Algerian guideline, stage III TNBC is managed with neoadjuvant chemotherapy + pembrolizumab.
- Pathological response after neoadjuvant treatment can influence subsequent therapy.
- BRCA1/2 testing can identify patients eligible for olaparib in the appropriate high-risk setting.
- The RCP has an increasingly important role in integrating pathology, biology, response and treatment access.
For years, triple-negative breast cancer (TNBC) was largely synonymous with chemotherapy. In Algeria, as elsewhere, this remains an important part of treatment—but the therapeutic approach is changing.
The 2026 Algerian Guides Thérapeutiques en Oncologie Médicale now incorporate immunotherapy and germline BRCA-directed treatment into the management of high-risk TNBC. For stage III disease, the recommended standard is neoadjuvant chemotherapy combined with pembrolizumab. The subsequent strategy is influenced by the pathological response obtained at surgery.
This represents an important shift in clinical practice.
The response to neoadjuvant treatment now matters
Neoadjuvant treatment is no longer simply a way to reduce tumour size before surgery. The pathological response provides information that can influence what happens next.
According to the 2026 Algerian guidelines, patients achieving a pathological complete response (pCR) after neoadjuvant chemo-immunotherapy do not receive additional systemic adjuvant treatment in this specific pathway.
This makes the post-operative pathology report increasingly important—not only for prognosis, but for treatment planning.
BRCA testing can change the pathway
TNBC should also prompt consideration of germline BRCA1/2 testing, particularly in patients in whom the result could influence treatment.
The Algerian 2026 guideline specifically includes one year of adjuvant olaparib for patients with a BRCA1/2 mutation in the relevant high-risk setting.
This means that the question in the RCP is no longer simply:
“Which chemotherapy should we give?”
It increasingly becomes:
“What is the tumour biology, what was the response to neoadjuvant therapy, and is there an actionable germline alteration?”
What does this mean for practice in Algeria?
The challenge is not only adopting new recommendations. It is making sure that the diagnostic pathway can support them.
For an Algerian patient with TNBC, treatment planning may now require coordinated access to pathology, appropriate biomarker assessment, genetic testing when indicated, surgery, radiotherapy and systemic therapy.
The RCP therefore becomes central: treatment decisions need to integrate stage, pathological response, BRCA status, comorbidities and access to the recommended treatments.
The evolution is significant, but implementation matters.
TNBC in Algeria is no longer simply a chemotherapy story. In 2026, treatment is increasingly being shaped by response, immunotherapy and molecular risk. The next challenge is ensuring that these advances can be translated consistently into patient care across the country.
